Sonoma Pharmaceuticals Short Interest Drops 27.8% in February

Decrease in short interest suggests reduced investor skepticism about the company's prospects.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant 27.8% decrease in short interest in February, with only 18,363 shares shorted as of February 13th compared to 25,448 shares at the end of January. The short-interest ratio also fell to 0.7 days, indicating reduced bearish sentiment towards the specialty dermatology company.

Why it matters

Short interest is a key indicator of investor sentiment, with a decline suggesting reduced skepticism about a company's outlook. For Sonoma Pharmaceuticals, this could signal growing confidence in the company's ability to execute on its strategy of developing and commercializing topical prescription and over-the-counter products for skin conditions.

The details

Sonoma Pharmaceuticals reported that short interest in its stock fell from 25,448 shares on January 29th to 18,363 shares as of February 13th, a 27.8% decrease. The short-interest ratio also dropped from 1.0 days to 0.7 days, meaning it would take less than a day for short sellers to cover their positions based on the stock's average daily trading volume.

  • Short interest data is as of February 13, 2026.
  • Sonoma Pharmaceuticals last reported earnings on February 10, 2026.

The players

Sonoma Pharmaceuticals, Inc.

A specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions.

Weiss Ratings

A financial research firm that recently reiterated a 'sell (e+)' rating on Sonoma Pharmaceuticals' stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The decline in short interest for Sonoma Pharmaceuticals suggests growing investor confidence in the company's ability to execute on its strategy and capitalize on opportunities in the specialty dermatology market. However, the stock still carries a 'sell' rating from one research firm, indicating that some skepticism remains around the company's prospects.